AI Agent Operational Lift for Epi Health, A Novan Company in Charleston, South Carolina

Why AI matters at this scale

EPI Health operates in the competitive specialty pharma space with 201-500 employees, a size where agility meets sufficient resources for digital transformation. As a Novan company, it commercializes prescription dermatology products, a sector where patient engagement and physician education are critical. At this mid-market scale, AI is not a moonshot—it's a practical lever to amplify commercial effectiveness without the overhead of big pharma. The company's direct-to-patient digital presence (epihealth.com) signals readiness for AI-enhanced customer journeys.

Three concrete AI opportunities with ROI framing

1. Intelligent patient support for adherence
The highest-ROI play is an AI-powered patient adherence platform. By combining a mobile app with machine learning, EPI Health can predict when a patient is likely to discontinue therapy and intervene with personalized nudges. A 10% improvement in refill rates for a flagship product could translate to millions in recurring revenue, directly impacting the bottom line within 12 months.

2. AI-augmented teledermatology network
Building a branded telehealth portal with integrated computer vision AI creates a powerful prescriber funnel. Patients upload images, AI pre-screens for conditions matching EPI's portfolio, and board-certified dermatologists confirm diagnoses and prescribe. This reduces time-to-treatment and builds a proprietary data asset on real-world product efficacy, strengthening payer negotiations.

3. Next-best-action engine for sales teams
Deploying a machine learning model on Veeva CRM data can score target physicians by propensity to prescribe. Instead of blanket territory coverage, reps receive AI-driven "next-best-action" recommendations—which HCP to visit, with what message, and when. This optimizes a major cost center and can lift sales force effectiveness by 15-20%.

Deployment risks specific to this size band

Mid-market pharma faces unique AI risks. Regulatory scrutiny from the FDA and OIG on promotional content means any generative AI used for marketing must have airtight guardrails to prevent off-label claims. Data privacy is paramount; a HIPAA breach from a poorly configured AI tool could be existential. Talent retention is another hurdle—data scientists may be lured away by larger tech or pharma firms. Mitigation involves starting with low-risk, internal-facing use cases, using established SaaS vendors with pharma-specific compliance, and creating a cross-functional AI governance committee from day one.